Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Trading Down 2.7 %

Shares of Minerva Neurosciences stock opened at $2.20 on Wednesday. Minerva Neurosciences has a 12-month low of $2.07 and a 12-month high of $13.49. The company has a market cap of $15.38 million, a P/E ratio of -5.00 and a beta of 0.11. The company’s fifty day simple moving average is $2.44 and its two-hundred day simple moving average is $2.77.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.